TOP TEN perturbations for 38928_r_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38928_r_at
Selected probe(set): 1555505_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38928_r_at (1555505_a_at) across 6674 perturbations tested by GENEVESTIGATOR:

expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic) / expO skin cancer study 1 (malignant melanoma, NOS; metastatic)

Relative Expression (log2-ratio):-7.7750034
Number of Samples:2 / 9
Experimental expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary squamous cell carcinoma (NOS) of the skin.
Control expO skin cancer study 1 (malignant melanoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary malignant melanoma (NOS) of the skin.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)

Relative Expression (log2-ratio):-6.1528263
Number of Samples:2 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)

Relative Expression (log2-ratio):-6.0400143
Number of Samples:3 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.

melanoma study 1 / normal skin tissue

Relative Expression (log2-ratio):5.733164
Number of Samples:3 / 4
Experimental melanoma study 1
Skin tissue from melanoma patients.
Control normal skin tissue
Normal skin tissue.

retina pigment epithelium study 1 (adult) / retina pigment epithelium study 1 (fetal)

Relative Expression (log2-ratio):-4.753809
Number of Samples:2 / 6
Experimental retina pigment epithelium study 1 (adult)
Postmortem human native retina pigment epithelium samples from adult individuals.
Control retina pigment epithelium study 1 (fetal)
Human native fetal retina pigment epithelium samples obtained at gestation age between week 16-18.

skin squamous cell carcinoma study 8 (primary) / melanoma study 34 (primary)

Relative Expression (log2-ratio):-3.7173834
Number of Samples:11 / 14
Experimental skin squamous cell carcinoma study 8 (primary)
Primary tumor tissue from the skin of patients with primary squamous cell carcinoma (SCC).
Control melanoma study 34 (primary)
Primary tumor tissue from the skin of patients with primary cutaneous melanoma (PCM). PCM consisted of 2 thin melanomas (< 1 mm; T1), 3 intermediate-thickness melanomas (1–4 mm; T2-3), and 9 thick melanomas (> 4 mm; T4).

basal cell carcinoma study 6 (primary) / melanoma study 34 (primary)

Relative Expression (log2-ratio):-3.181675
Number of Samples:15 / 14
Experimental basal cell carcinoma study 6 (primary)
Primary tumor tissue from the skin of patients with primary basal cell carcinoma (BCC).
Control melanoma study 34 (primary)
Primary tumor tissue from the skin of patients with primary cutaneous melanoma (PCM). PCM consisted of 2 thin melanomas (< 1 mm; T1), 3 intermediate-thickness melanomas (1–4 mm; T2-3), and 9 thick melanomas (> 4 mm; T4).

melanoma study 34 (primary) / normal skin tissue

Relative Expression (log2-ratio):2.3354406
Number of Samples:14 / 4
Experimental melanoma study 34 (primary)
Primary tumor tissue from the skin of patients with primary cutaneous melanoma (PCM). PCM consisted of 2 thin melanomas (< 1 mm; T1), 3 intermediate-thickness melanomas (1–4 mm; T2-3), and 9 thick melanomas (> 4 mm; T4).
Control normal skin tissue
Normal skin tissue.

basal cell carcinoma study 3 / normal epidermal keratinocytes

Relative Expression (log2-ratio):2.306489
Number of Samples:4 / 2
Experimental basal cell carcinoma study 3
Primary tumor tissue from the eyelid of patients with basal cell carcinoma (BCC).
Control normal epidermal keratinocytes
Normal human epidermal keratinocytes (NHEK) (Kurabo Ind., Ltd., Osaka, Japan) cultured in HuMedia-KB2 medium at 37°C in humidified air containing 5% CO2.

skin transplantation study 1 (7d) / normal skin tissue (skin grafting)

Relative Expression (log2-ratio):-2.284607
Number of Samples:5 / 8
Experimental skin transplantation study 1 (7d)
Human skin punch biopsy from patients after skin grafting. Sample was taken at the site of re-epithelialization 7 days after surgery.
Control normal skin tissue (skin grafting)
Skin biopsy samples from healthy control subjects after breast or abdomen reduction surgery.

Organism: Homo sapiens
Gene: 38928_r_at
Selected probe(set): 206630_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38928_r_at (206630_at) across 6674 perturbations tested by GENEVESTIGATOR:

expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic) / expO skin cancer study 1 (malignant melanoma, NOS; metastatic)

Relative Expression (log2-ratio):-7.1174297
Number of Samples:2 / 9
Experimental expO skin cancer study 1 (squamous cell carcinoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary squamous cell carcinoma (NOS) of the skin.
Control expO skin cancer study 1 (malignant melanoma, NOS; metastatic)
Metastatic tumor tissue samples obtained from patients with primary malignant melanoma (NOS) of the skin.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)

Relative Expression (log2-ratio):-6.4377327
Number of Samples:2 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)

Relative Expression (log2-ratio):-6.2523327
Number of Samples:3 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.

melanoma study 1 / normal skin tissue

Relative Expression (log2-ratio):4.1646194
Number of Samples:3 / 4
Experimental melanoma study 1
Skin tissue from melanoma patients.
Control normal skin tissue
Normal skin tissue.

retina pigment epithelium study 1 (adult) / retina pigment epithelium study 1 (fetal)

Relative Expression (log2-ratio):-3.7455206
Number of Samples:2 / 6
Experimental retina pigment epithelium study 1 (adult)
Postmortem human native retina pigment epithelium samples from adult individuals.
Control retina pigment epithelium study 1 (fetal)
Human native fetal retina pigment epithelium samples obtained at gestation age between week 16-18.

Merkel cell carcinoma study 3 (primary) / basal cell carcinoma study 2

Relative Expression (log2-ratio):-3.5859146
Number of Samples:19 / 2
Experimental Merkel cell carcinoma study 3 (primary)
Primary tumor tissue from the skin of patients with Merkel cell carcinoma.
Control basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).

skin squamous cell carcinoma study 8 (primary) / melanoma study 34 (primary)

Relative Expression (log2-ratio):-3.255952
Number of Samples:11 / 14
Experimental skin squamous cell carcinoma study 8 (primary)
Primary tumor tissue from the skin of patients with primary squamous cell carcinoma (SCC).
Control melanoma study 34 (primary)
Primary tumor tissue from the skin of patients with primary cutaneous melanoma (PCM). PCM consisted of 2 thin melanomas (< 1 mm; T1), 3 intermediate-thickness melanomas (1–4 mm; T2-3), and 9 thick melanomas (> 4 mm; T4).

skin squamous cell carcinoma study 6 / basal cell carcinoma study 2

Relative Expression (log2-ratio):-3.0376577
Number of Samples:4 / 2
Experimental skin squamous cell carcinoma study 6
Primary tumor tissue from the skin of patients with squamous cell carcinoma (SCC).
Control basal cell carcinoma study 2
Primary tumor tissue from the skin of patients with basal cell carcinoma (BCC).

basal cell carcinoma study 6 (primary) / melanoma study 34 (primary)

Relative Expression (log2-ratio):-2.68777
Number of Samples:15 / 14
Experimental basal cell carcinoma study 6 (primary)
Primary tumor tissue from the skin of patients with primary basal cell carcinoma (BCC).
Control melanoma study 34 (primary)
Primary tumor tissue from the skin of patients with primary cutaneous melanoma (PCM). PCM consisted of 2 thin melanomas (< 1 mm; T1), 3 intermediate-thickness melanomas (1–4 mm; T2-3), and 9 thick melanomas (> 4 mm; T4).

split-thickness skin grafting study 1 / normal skin tissue (skin grafting)

Relative Expression (log2-ratio):-2.6606922
Number of Samples:6 / 8
Experimental split-thickness skin grafting study 1
Skin punch biopsy from patients with skin injury (burn injury, congelation, wound, compartment syndrome) immediately after split-thickness skin grafting was done. Sample was taken from the acute wound after grafting.
Control normal skin tissue (skin grafting)
Skin biopsy samples from healthy control subjects after breast or abdomen reduction surgery.